[4A5-4A5];[4C13-4C13];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
4A5;4C13
Breakpoint based on progenitor insertion release 3 sequence coordinate X:4428693 , per R. Hoskins (Gene Disruption Project) personal communication, mapped forward to release 5.
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
The presence of P+PBac{XP5.WH5}BSC580 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d01801 to be Release 3 genomic coordinate 4428687 on the X chromosome. The Gene Disruption project determined the insertion site of P{XP}d01801 to be Release 3 genomic coordinate 4428693 on the X chromosome. This corresponds to 4C13 on the Release 3 and Release 5 genome maps. The predicted position of PBac{WH}f05811 on the Release 5 map is 4A5. Consequently, the cytological breakpoints of Df(1)BSC580 are predicted to be 4A5;4C13.